Matches in Wikidata for { <http://www.wikidata.org/entity/Q62475955> ?p ?o ?g. }
Showing items 1 to 61 of
61
with 100 items per page.
- Q62475955 description "articolo scientifico (pubblicato il 2018)" @default.
- Q62475955 description "artikull shkencor i botuar më 01 shkurt 2018" @default.
- Q62475955 description "artículu científicu espublizáu en febreru de 2018" @default.
- Q62475955 description "im Februar 2018 veröffentlichter wissenschaftlicher Artikel" @default.
- Q62475955 description "scientific article published on 01 February 2018" @default.
- Q62475955 description "wetenschappelijk artikel" @default.
- Q62475955 description "наукова стаття, опублікована в лютому 2018" @default.
- Q62475955 name "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 name "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 name "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 type Item @default.
- Q62475955 label "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 label "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 label "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 prefLabel "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 prefLabel "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 prefLabel "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 P1433 Q62475955-6E3EABB8-BB1C-48B6-8953-EF8136CB1025 @default.
- Q62475955 P1476 Q62475955-26B18D3D-1612-4A7D-B45A-AEF803107D92 @default.
- Q62475955 P2093 Q62475955-3A6A9711-E7D5-4EC0-96DB-501B9A875711 @default.
- Q62475955 P2093 Q62475955-4CDAB72E-4C2C-49CA-A4B4-C39CCC51FA89 @default.
- Q62475955 P2093 Q62475955-51437378-63E2-4EE2-9524-546C4166B815 @default.
- Q62475955 P2093 Q62475955-562F5942-8428-4614-A9C7-66574036CF9F @default.
- Q62475955 P2093 Q62475955-885E6844-87DA-4476-98D6-3B82CA7A9344 @default.
- Q62475955 P2093 Q62475955-AAFA81D6-B2B4-4837-8680-128A7087FE66 @default.
- Q62475955 P2093 Q62475955-BB3F9651-E3C1-4F8E-8FC3-D50E6C4C71DF @default.
- Q62475955 P2093 Q62475955-C242B93D-A8D3-421B-A7BA-9BE5C1726B06 @default.
- Q62475955 P2093 Q62475955-E0E10BE3-35F1-427A-9242-413FC85822F7 @default.
- Q62475955 P304 Q62475955-FD88507F-2542-4D6A-B72A-8A651A473B06 @default.
- Q62475955 P31 Q62475955-576633EE-4ACC-431A-8111-26AD884A485C @default.
- Q62475955 P356 Q62475955-5F4615BC-5D9A-4E9C-9B30-82EBB129E203 @default.
- Q62475955 P433 Q62475955-B37613D0-FC5B-4CA5-9DAC-8A2E1E5EFEE2 @default.
- Q62475955 P478 Q62475955-06580F29-2B30-4D27-B4EB-7F119B87ED73 @default.
- Q62475955 P50 Q62475955-C61E55E6-5F47-4883-81EE-1B1E981BDE29 @default.
- Q62475955 P50 Q62475955-CBD43973-23DB-4086-88C1-D740DFDEC4AB @default.
- Q62475955 P577 Q62475955-FC6B13E6-DD06-49E4-9904-33454D1B2384 @default.
- Q62475955 P698 Q62475955-7729D722-7130-479A-92A6-1CB655D2FB67 @default.
- Q62475955 P921 Q62475955-53BF913E-8929-4D6E-91DB-C40D99C90BDF @default.
- Q62475955 P356 IZX086 @default.
- Q62475955 P698 29462398 @default.
- Q62475955 P1433 Q15749161 @default.
- Q62475955 P1476 "Full Interchangeability in Regard to Immunogenicity Between the Infliximab Reference Biologic and Biosimilars CT-P13 and SB2 in Inflammatory Bowel Disease" @default.
- Q62475955 P2093 "Ainara Maguregui" @default.
- Q62475955 P2093 "Antonio Martínez" @default.
- Q62475955 P2093 "Carmen Correale" @default.
- Q62475955 P2093 "Daniel Nagore" @default.
- Q62475955 P2093 "Daniela Gilardi" @default.
- Q62475955 P2093 "Federica Furfaro" @default.
- Q62475955 P2093 "M Begoña Ruiz-Argüello" @default.
- Q62475955 P2093 "Mariangela Allocca" @default.
- Q62475955 P2093 "Simona Radice" @default.
- Q62475955 P304 "601-606" @default.
- Q62475955 P31 Q13442814 @default.
- Q62475955 P356 "10.1093/IBD/IZX086" @default.
- Q62475955 P433 "3" @default.
- Q62475955 P478 "24" @default.
- Q62475955 P50 Q37837552 @default.
- Q62475955 P50 Q89573798 @default.
- Q62475955 P577 "2018-02-01T00:00:00Z" @default.
- Q62475955 P698 "29462398" @default.
- Q62475955 P921 Q917447 @default.